A Single Drug Propels TG Therapeutics Into Biotech Contention

Could one therapy transform an underfunded biotech into a market leader? TG Therapeutics is making a compelling case with its multiple sclerosis drug, BRIUMVI, demonstrating how commercial success and strategic expansion can drive a remarkable corporate turnaround. After a significant share price advance, the company is not pausing but is instead building momentum through both financial performance and pipeline development.

The most recent quarterly figures serve as a powerful testament to BRIUMVI’s market acceptance. The therapy generated $138.8 million in U.S. net sales, representing a substantial 91.2% increase year-over-year. This overwhelming demand prompted management to significantly raise its full-year financial guidance, now projecting revenue between $575 million and $585 million. The drug’s efficacy and tolerability profile appear to be resonating strongly with both... Read more...